Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
VanderWerf
B A
BA
Good Samaritan Regional Medical Center and Phoenix Children's Hospital, Arizona, USA.
D002102:Cadaver; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology*; D007683:Kidney Tubular Necrosis, Acute / Q000628:therapy*; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D016572:Cyclosporine